Zimmer Holdings Inc. Release: Prospective Clinical Advantages of Trabecular Metal(TM) Technology Highlighted in Comparative Study

WARSAW, Ind., July 20 /PRNewswire-FirstCall/ -- Zimmer Holdings, Inc. (NYSE: ZMH - News; SWX: ZMH - News) today announced that data from a comparative clinical study conducted by researchers at the Mayo Clinic and the Joint Replacement Surgeons of the Indiana Research Foundation describes the low stiffness and osteoconductive properties of Zimmer’s Trabecular Metal Technology. The study, published in The Journal of Arthroplasty, found significant reductions in acetabular bone loss adjacent to the Trabecular Metal device compared to the titanium component, and a significant relative increase in bone mineral density (BMD) after total hip arthroplasty (THA) using implants made with Zimmer’s proprietary Trabecular Metal Technology.

MORE ON THIS TOPIC